Los Angeles Capital Management’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-124,357
| Closed | -$3.08M | – | 2362 |
|
|
2026
Q1 | $3.08M | Sell |
124,357
-12,242
| -9% | -$292K | 0.01% | 413 |
|
|
2025
Q4 | $2.86M | Sell |
136,599
-25,800
| -16% | -$575K | 0.01% | 381 |
|
|
2025
Q3 | $3.2M | Sell |
162,399
-21,976
| -12% | -$452K | 0.01% | 401 |
|
|
2025
Q2 | $4M | Sell |
184,375
-3,941
| -2% | -$93K | 0.02% | 337 |
|
|
2025
Q1 | $4.57M | Sell |
188,316
-15,708
| -8% | -$354K | 0.02% | 304 |
|
|
2024
Q4 | $4.26M | Buy |
204,024
+3,742
| +2% | +$80.4K | 0.02% | 342 |
|
|
2024
Q3 | $3.98M | Buy |
200,282
+123,020
| +159% | +$2.28M | 0.02% | 340 |
|
|
2024
Q2 | $1.2M | Sell |
77,262
-3,755
| -5% | -$58.5K | ﹤0.01% | 599 |
|
|
2024
Q1 | $1.29M | Buy |
81,017
+35,066
| +76% | +$528K | ﹤0.01% | 609 |
|
|
2023
Q4 | $772K | Sell |
45,951
-41,330
| -47% | -$565K | ﹤0.01% | 757 |
|
|
2023
Q3 | $1.02M | Sell |
87,281
-941
| -1% | -$12.6K | ﹤0.01% | 638 |
|
|
2023
Q2 | $1.19M | Sell |
88,222
-21,951
| -20% | -$316K | ﹤0.01% | 615 |
|
|
2023
Q1 | $1.83M | Sell |
110,173
-17,462
| -14% | -$288K | 0.01% | 517 |
|
|
2022
Q4 | $2.37M | Sell |
127,635
-13,907
| -10% | -$214K | 0.01% | 478 |
|
|
2022
Q3 | $1.82M | Sell |
141,542
-226,092
| -61% | -$2.68M | 0.01% | 524 |
|
|
2022
Q2 | $2.58M | Buy |
367,634
+131,159
| +55% | +$962K | 0.01% | 472 |
|
|
2022
Q1 | $1.96M | Sell |
236,475
-50,370
| -18% | -$356K | 0.01% | 538 |
|
|
2021
Q4 | $1.94M | Buy |
286,845
+55,880
| +24% | +$367K | 0.01% | 523 |
|
|
2021
Q3 | $1.22M | Buy |
230,965
+57,180
| +33% | +$313K | 0.01% | 677 |
|
|
2021
Q2 | $999K | Buy |
+173,785
| New | +$897K | ﹤0.01% | 859 |
|
|
2021
Q1 | – | Sell |
-362,065
| Closed | -$1.21M | – | 1591 |
|
|
2020
Q4 | $1.21M | Sell |
362,065
-26,320
| -7% | -$88.4K | 0.01% | 852 |
|
|
2020
Q3 | $1.15M | Sell |
388,385
-86,485
| -18% | -$338K | 0.01% | 769 |
|
|
2020
Q2 | $2.19M | Buy |
474,870
+159,865
| +51% | +$718K | 0.01% | 594 |
|
|
2020
Q1 | $1.21M | Buy |
315,005
+208,445
| +196% | +$856K | 0.01% | 664 |
|
|
2019
Q4 | $400K | Buy |
106,560
+3,350
| +3% | +$15.7K | ﹤0.01% | 1064 |
|
|
2019
Q3 | $548K | Buy |
103,210
+8,250
| +9% | +$44K | ﹤0.01% | 955 |
|
|
2019
Q2 | $365K | Buy |
94,960
+52,260
| +122% | +$226K | ﹤0.01% | 1125 |
|
|
2019
Q1 | $218K | Hold |
42,700
| – | – | ﹤0.01% | 1285 |
|
|
2018
Q4 | $82K | Sell |
42,700
-200
| -0.5% | -$573 | ﹤0.01% | 1244 |
|
|
2018
Q3 | $162K | Buy |
42,900
+25,940
| +153% | +$81.3K | ﹤0.01% | 1353 |
|
|
2018
Q2 | $53K | Buy |
+16,960
| New | +$51.5K | ﹤0.01% | 1424 |
|
Other funds holding CPRX
GCL
HI
Los Angeles Capital Management's CPRX Position: Q2 2026 in Review
Los Angeles Capital Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 124,357 shares — an estimated $3.08M sold.
Los Angeles Capital Management first reported a position in CPRX in Q2 2018 and held it in 31 quarters. The position peaked at $4.57M in Q1 2025. 395 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.
- Los Angeles Capital Management reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
- Los Angeles Capital Management sold 124,357 Catalyst Pharmaceutical shares in Q2 2026, an estimated $3.08M.
- Los Angeles Capital Management first reported a position in Catalyst Pharmaceutical in Q2 2018 and held it in 31 quarters.
- Los Angeles Capital Management's Catalyst Pharmaceutical position peaked at $4.57M in Q1 2025.
- 395 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.
Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.